Drug intelligence / Profile preview

PECCOM

Development stage: Unknown
Lead developer: Reber Genetics
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**PECCOM** is a Reber Genetics veterinary bivalent protein-subunit vaccine intended to protect pigs against co-infection with porcine reproductive and respiratory syndrome virus and porcine circovirus type 2. It combines antigens directed at both pathogens to induce protective humoral and cellular immune responses. Reber Genetics' pipeline identified PECCOM as having received market authorization in 2019 for swine PRRS and PCV2 co-infection.

Beyond the preview

Go deeper on PECCOM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PECCOM.

Explore the full profile